[Innovations in systemic treatment of urothelial carcinoma]

Abstract

Until 2014, no new therapeutic agent have been approved by authorities in more than 2 decades for bladder cancer. But the panel of treatments has expended in recent years with the emergence of at least 3 different therapeutic classes. First, the immune checkpoint inhibitors that have demonstrated an overall survival benefit in metastatic patients after failure of platinum based chemotherapy. They are therefore currently evaluated alone or in combination with chemotherapy in multiple studies at earlier stages (localized and meta-static). The second and third therapeutic classes are the targeted therapies (especially FGFR inhibitor) and the antibody-drug conjugates with promising results in early clinical trials. In this article, we review all the current and future studies conducted in urothelial carcinoma of the bladder.

Keywords: Anti-FGFR; Anti-PARP; Anticorps conjugués; Carcinome urothélial; Drug-conjugate; Immune checkpoint; Immunothérapie; Inhibiteurs; Targeted therapy; Thérapies ciblées; Urothelial carcinoma; antibody; de checkpoint; immunologique; inhibitors.